Fervent Pharmaceuticals Receives Another Patent Related To Menopause Product
Fervent Pharmaceuticals is happy to announce another patent has been allowed for its upcoming vasomotor symptom treatment FP-101 in Eurasia. This newest patent joins over a dozen other patents, both in the United States and abroad, that have been granted since 2013.
FP-101 is an oral formulation that has been shown in preliminary studies to be effective in treating vasomotor symptoms like hot flashes, night sweats, and insomnia. It’s a non-hormonal/non-herbal existing compound that is FDA-approved for another indication and has a long history of safe use.
“Our growing patent portfolio is a valuable asset as we continue to develop our unique menopause symptom treatment,” Fervent CEO George Royster noted. “Our patents give FP-101 global market coverage and are a strong vote of confidence in our product.”
Three more patents for FP-101 are currently pending, and are expected to be granted in 2017. The treatment is currently in the final stages of development. Fervent will begin recruiting patients for Phase II trials in 2017.